Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

562 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting.
Fabbiani M, Lombardi A, Colaneri M, Del Poggio P, Perini P, D'Ambrosio R, Degasperi E, Dibenedetto C, Giorgini A, Pasulo L, Maggiolo F, Castelli F, Brambilla P, Spinelli O, Re T, Lleo A, Rumi M, Uberti-Foppa C, Soria A, Aghemo A, Lampertico P, Baiguera C, Schiavini M, Fagiuoli S, Bruno R; NAVIGATORE-Lombardia Study Group. Fabbiani M, et al. Among authors: lleo a. J Viral Hepat. 2021 Mar;28(3):558-568. doi: 10.1111/jvh.13454. Epub 2021 Jan 2. J Viral Hepat. 2021. PMID: 33306247
Innate immunity and primary biliary cirrhosis.
Selmi C, Lleo A, Pasini S, Zuin M, Gershwin ME. Selmi C, et al. Among authors: lleo a. Curr Mol Med. 2009 Feb;9(1):45-51. doi: 10.2174/156652409787314525. Curr Mol Med. 2009. PMID: 19199941 Review.
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. Di Maio VC, et al. Liver Int. 2017 Apr;37(4):514-528. doi: 10.1111/liv.13327. Epub 2017 Jan 20. Liver Int. 2017. PMID: 28105744
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.
Persico M, Aglitti A, Aghemo A, Rendina M, Lleo A, Ciancio A, Di Marco V, Lampertico P, Brunetto MR, Zuin M, Andreone P, Villa E, Troshina G, Calvaruso V, Degasperi E, Coco B, Giorgini A, Conti F, Di Leo A, Marzi L, Boccaccio V, Bollani S, Maisonneuve P, Bruno S. Persico M, et al. Among authors: lleo a. Aliment Pharmacol Ther. 2018 Jun;47(12):1705-1712. doi: 10.1111/apt.14685. Epub 2018 May 3. Aliment Pharmacol Ther. 2018. PMID: 29722439
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era.
Spadaccini M, Lleo A, Ceriani R, Covini G, Rimassa L, Torzilli G, Di Tommaso L, Aghemo A. Spadaccini M, et al. Among authors: lleo a. Hepatobiliary Pancreat Dis Int. 2018 Dec;17(6):570-574. doi: 10.1016/j.hbpd.2018.10.006. Epub 2018 Oct 28. Hepatobiliary Pancreat Dis Int. 2018. PMID: 30420319 No abstract available.
562 results